adxs11-001 immunotherapy targeting hpv -e7:...

ADXS11-001 immunotherapy targeting HPV-E7: Final results from a Phase 2 study in Indian women with recurrent cervical cancer Abstract Life Cycle of Lm in APC Lm-LLO Immunotherapy KM Curve & Overall Survival Lm-LLO-E7-15 Tumor Response Data Conclusions Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety & Efficacy of ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer Trial Design: Lm-LLO-E7-15 Safety Summaries: Lm-LLO-E7-15 Participating Sites in India General Demographics CR and PR Case Studies CT Scan Evaluation at 3, 6, 9, 12 and 18 months Patient Demographics of Long Term Survivors ( > 18M) Partha Basu 1 , Ajay Mehta 2 , Minish Jain 3 , Sudeep Gupta 4 , Rajnish Nagarkar 5 , Vijay Kumar 6 , Sumana Premkumar 7 , Rakesh Neve 8 , Subhashini John 9 , and Robert Petit 10 1 Chittaranjan National Cancer Institute, Kolkata, India, 2 Central India Cancer Research Institute, 3 Ruby Hall Clinic, 4 Tata Memorial Hospital, 5 Curie Manavata Cancer Center, India, 6 MV Hospital and Research Center, 7 Dr. Kamakshi Memorial Hospital, 8 Smt. Kashibai Navale Medical College and General Hospital, 9 Christian Medical College Vellore, 10 Advaxis, Inc. Princeton, NJ

Upload: others

Post on 06-Aug-2020

6 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: ADXS11-001 immunotherapy targeting HPV -E7: …content.stockpr.com/advaxis/media/28eea9b11b564f10ce912d...ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer Trial Design:

ADXS11-001 immunotherapy targeting HPV-E7: Final results from a Phase 2 study in Indian women with recurrent cervical cancer

Abstract

Life Cycle of Lm in APC

Lm-LLO Immunotherapy

KM Curve & Overall Survival

Lm-LLO-E7-15 Tumor Response Data Conclusions

Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety & Efficacy of ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer

Trial Design: Lm-LLO-E7-15

Safety Summaries: Lm-LLO-E7-15

Participating Sites in India

General Demographics

CR and PR Case Studies CT Scan Evaluation at 3, 6, 9, 12 and 18 months

Patient Demographics of Long Term Survivors ( >18M)

Partha Basu1, Ajay Mehta2, Minish Jain3, Sudeep Gupta4, Rajnish Nagarkar5, Vijay Kumar6, Sumana Premkumar7, Rakesh Neve8, Subhashini John9, and Robert Petit10

1Chittaranjan National Cancer Institute, Kolkata, India, 2Central India Cancer Research Institute, 3 Ruby Hall Clinic, 4Tata Memorial Hospital, 5Curie Manavata Cancer Center, India, 6 MV Hospital and Research Center, 7 Dr. Kamakshi Memorial Hospital,8 Smt. Kashibai Navale Medical College and General Hospital, 9 Christian Medical College Vellore, 10Advaxis, Inc. Princeton, NJ

ADXS11-001 immunotherapy targeting HPV-E7: Updated survival …content.equisolve.net/advaxis/media/1e59a6095559fead4a... · 2016-01-09 · ADXS11-001 immunotherapy targeting HPV-E7:

Vacinação HPV

HPV Official

pathos223.com144 111 HPV b . inset : HPV HPV inset glo Z Z. HPV < Papanicolaou class Illa HPV 11 STD 11 Z. verrucous carcinoma 1) De Villiers, E-M. : Human pathogenic papilloma virus

VÍRUS HPV CONTÁGIO E DESENVOLVIMENTO NO CORPO PATOLOGIA DO HPV PREVENÇÃO EXAMES TRATAMENTOS HPV NO HOMEM VACINA CONTRA HPV QUEM PODE SE

Hpv Manual

ADXS11-001 IMMUNOTHERAPY: 12 MONTH SURVIVAL AND …content.equisolve.net/advaxis/media/e0e1d38f7024f8f0e534eb6fcb9… · dition of cisplatin to ADXS11-001 in this study did not significantly

HPV Presenation

HPV Construction_reduced

Effect of HPV-vaccination on HPV-prevalence in Belgium - Gene

Techtron HPV

EXPOSIÇÃO : CASOS CLÍNICOS - bvsms.saude.gov.brbvsms.saude.gov.br/bvs/palestras/cancer/exposicoes... · Ca escamoso AdenoCa Adenoescam Neuroendocrino. HPV 16 HPV 18 HPV 18 HPV